A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPR741 in Healthy Volunteers
Latest Information Update: 05 Jul 2019
At a glance
- Drugs SPR 741 (Primary)
- Indications Gram-negative infections
- Focus Adverse reactions; First in man
- Sponsors Spero Therapeutics
- 01 Jul 2019 Results from SPR741-101s and SPR741-102 studies were published in the Antimicrobial Agents and Chemotherapy.
- 24 Apr 2018 Results presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases
- 24 Apr 2018 Pharmacokinetic results presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases